The particular calcium (CA2+) that leronlimab controls is intracellular calcium. CA2+ is released into the bloodstream from bone by inflammatory factors which can use this to enhance activities of the disease state. An excessive amount of CA2+ release can mean greater loss of CA2+ through the kidneys. Leronlimab would tend to reduce bone loss when that bone loss is related to upregulation of cytokines. When I first posted my disease list I looked at osteoporosis but with the multiple other factors involved in the disease it didn't make the cut.